PD-L1 Targeting Molecular Imaging of Solid Tumors

Peking University Cancer Hospital & Institute

Status: Enrolling

Conditions: Gastrointestinal Tumors

Treatments: Other: 68Ga-WL12 PET/CT

Study type: Interventional

Funder types: Other

Identifiers

NCT04629326

WL12-Tumor

Details and patient eligibility

About

The objective of the study is to constrcut a noninvasive approach WL12 PET/CT to detect the PD-L1 expression of tumor lesions in patients with gastrointestinal tumors and to identify patients benefiting from anti-PD-1/L1 treatment.

Enrollment: 20 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 1. Aged >18 years old; ECOG 0 or 1;
• 2. Patients with Gastrointestinal tumors;
• 3. Has at least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST V1.1);
• 4. life expectancy >=12 weeks.

Exclusion criteria

• 1. Significant hepatic or renal dysfunction;
• 2. Is pregnant or ready to pregnant;
• 3. Cannot keep their states for half an hour;
• 4. Refusal to join the clinical study;
• 5. Suffering from claustrophobia or other mental diseases;
• 6. Any other situation that researchers think it is not suitable to participate in the experiment.

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

20 participants in 1 patient group

Imaging cohort

Experimental group

Description:

All study participants will be allocated to this arm (single-arm study).Study participants will undergo 68Ga-WL12 PET/CT scans

Treatment:

Other: 68Ga-WL12 PET/CT